A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Clinical trial NCT02406742 · COMPLETED

Trial details

NCT number: NCT02406742
Sponsor: Celgene
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Leukemia, Lymphocytic, Chronic, B-Cell

Start date: 2015-07-27
Primary completion: 2020-07-07
Enrollment: 47

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.